^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCRI-CAR22v2

    i
    Associations
    News

    Trials

    Company:
    Seattle Children's Hospital
    Drug class:
    CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma (NCT04571138)
    Phase 1/2
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    09/25/2020
    Primary completion :
    06/01/2025
    Completion :
    02/01/2040
    CD22
    |
    SCRI-CAR22v2